Certara, Inc. CERT 深 滬
等待開盤 04-01 09:30:00 美东时间
5.70
+0.020
+0.35%
華盛通- 最 高5.89
- 今 開5.78
- 成交量 999.80万股
- 最 低 5.60
- 昨 收 5.68
- 總市值 9.06亿
- 52周最高 15.38
- 市盈率 靜 --
- 換手率 6.29%
- 52周最低 5.60
- 委 比 68.34%
- 總股本 1.59亿
- 歷史最高 45.48
- 量 比 2.21
- 振 幅 5.11%
- 歷史最低 5.60
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
Medpace, IQVIA upgraded at Barclays; says AI concerns are overdone
As part of a broader review of life science and diagnostic tools stocks, Barclays upgraded contract research organizations IQVIA Holdings (IQV) and Medpace Holdings (MEDP) on Friday, noting that conce...
03-07 02:44
BRIEF-Certara Simcyp® Simulator Results Replace Ten Human Trials For Chronic Myeloid Leukemia (Cml) Therapy Asciminib
BRIEF-Certara Simcyp® Simulator Results Replace Ten Human Trials For Chronic Myeloid Leukemia (Cml) Therapy Asciminib March 3 (Reuters) - Certara Inc CERT.O : CERTARA SIMCYP® SIMULATOR RESULTS REPLACE TEN HUMAN TRIALS FOR CHRONIC MYELOID LEUKEMIA (CML) THERAPY ASCIMINIB Source text: ID:nGNX12MPg3 Fu
03-03 21:04
Certara Simcyp PBPK Modeling Replaces Ten Asciminib Trials in FDA NDA Support
Certara Simcyp PBPK Modeling Replaces Ten Asciminib Trials in FDA NDA Support Certara Inc. said its Simcyp Simulator enabled physiologically-based pharmacokinetic (PBPK) modeling predictions that were accepted by the U.S. FDA in lieu of clinical studies to support the new drug application for ascimi
03-03 21:03
Certara Simcyp Modeling Replaces 10 Human Trials in FDA Asciminib NDA Support
Certara Simcyp Modeling Replaces 10 Human Trials in FDA Asciminib NDA Support Certara Inc. announced that its Simcyp Simulator supported physiologically-based pharmacokinetic modeling for asciminib (Scemblix) that was accepted by the U.S. FDA in lieu of clinical studies for the drug’s new drug appli
03-03 21:01
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib
Biosimulation highlights model-informed approaches save time and money in drug development and regulatory decision-making. Certara's Simcyp Simulator enabled PBPK modeling predictions accepted by the U.S. FDA for asciminib's NDA. PBPK modeling predicts drug absorption, distribution, metabolism, and elimination, replacing clinical studies where appropriate. Asciminib, a first-in-class allosteric inhibitor for Chronic Myeloid Leukemia (CML), treate...
03-03 13:00
美股大行评级 | 下调居多！多邻国、Elastic、Flutter、欧特克、Zscaler等遭多家机构下调目标价
今日重点评级关注：巴克莱：维持C4 Therapeutics"超配"评级，目标价从5美元升至7美元；富国银行：维持Agilon Health"超配"评级，目标价从1美元升至1.5美元
03-02 14:08
Barclays Maintains Overweight on Certara, Lowers Price Target to $8
Barclays analyst Luke Sergott maintains Certara (NASDAQ:CERT) with a Overweight and lowers the price target from $13 to $8.
02-27 23:10
财报速睇 | Certara, Inc. 2025财年年度营收4.19亿美元，同比增长8.7%；归母净利润亏损0.02亿美元，同比亏损缩窄86.8%
华盛资讯2月26日讯，Certara, Inc.公布2025财年年度业绩，公司年度营收4.19亿美元，同比增长8.7%，归母净利润亏损0.02亿美元，同比亏损缩窄86.8%。
02-26 20:36
Earnings Breakdown: Certara Q4
Certara (NASDAQ:CERT) announced its Q4 earnings on Thursday, February 26, 2026 ...
02-26 20:04
